INT480

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1979
Last Reported 2010
Negated 1
Speculated 1
Reported most in Abstract
Documents 151
Total Number 152
Disease Relevance 27.64
Pain Relevance 63.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Avp) extracellular space (Avp) extracellular region (Avp)
response to stress (Avp) signal transducer activity (Avp)
Anatomy Link Frequency
neurohypophysis 26
plasma 10
neural lobe 10
nucleus 8
hypothalamus 8
Avp (Rattus norvegicus)
Pain Link Frequency Relevance Heat
narcan 171 100.00 Very High Very High Very High
opiate 100 100.00 Very High Very High Very High
Enkephalin 83 100.00 Very High Very High Very High
Clonidine 72 100.00 Very High Very High Very High
gABA 59 100.00 Very High Very High Very High
orphanin 11 100.00 Very High Very High Very High
depression 4 100.00 Very High Very High Very High
agonist 155 99.98 Very High Very High Very High
Opioid 105 99.98 Very High Very High Very High
MU agonist 53 99.98 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 70 100.00 Very High Very High Very High
Depression 4 100.00 Very High Very High Very High
Hypoglycemia 1 99.98 Very High Very High Very High
Body Weight 15 99.96 Very High Very High Very High
Diuresis 66 99.92 Very High Very High Very High
Hypertension 15 99.68 Very High Very High Very High
Pain 17 99.64 Very High Very High Very High
Pressure Volume 2 Under Development 35 99.52 Very High Very High Very High
Shock 7 99.48 Very High Very High Very High
Natriuresis 33 99.36 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Intracerebroventricular administration of leumorphin (600 pmol) also reduced the AVP secretion stimulated by icv injection of carbachol (50 pmol).
Negative_regulation (reduced) of Localization (secretion) of AVP associated with intracerebroventricular
1) Confidence 0.59 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.24
In 72-h water-deprived rats, icv injection of leumorphin (60 or 600 pmol) also suppressed AVP secretion in a dose-dependent manner.
Negative_regulation (suppressed) of Localization (secretion) of AVP
2) Confidence 0.59 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.25
Intracerebroventricular injection of leumorphin (60 or 600 pmol) significantly inhibited basal AVP secretion.
Negative_regulation (inhibited) of Localization (secretion) of AVP associated with intracerebroventricular
3) Confidence 0.59 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.25
Intravenous pretreatment with naloxone (0.5 mg/kg BW) diminished the inhibitory action of leumorphin (60 pmol) on AVP secretion.
Negative_regulation (diminished) of Localization (secretion) of AVP associated with narcan
4) Confidence 0.59 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.23
A new experimental rat model for suppression of release of arginine vasopressin (AVP) was evaluated.
Negative_regulation (suppression) of Localization (release) of AVP
5) Confidence 0.59 Published 1998 Journal Lab. Anim. Sci. Section Abstract Doc Link 10090042 Disease Relevance 0.41 Pain Relevance 0.08
Prior administration of U50 488H also attenuated the potentiating effect of naloxone on AVP secretion stimulated by i.c.v. injection of hypertonic NaCl.
Negative_regulation (attenuated) of Localization (secretion) of AVP associated with narcan
6) Confidence 0.59 Published 1991 Journal J. Endocrinol. Section Abstract Doc Link 1648591 Disease Relevance 0 Pain Relevance 0.65
These studies suggest that the ethanol induced diuresis commonly ascribed to inhibition of AVP secretion may also be due to other intrarenal effects of ethanol, possibly acting within the proximal tubule.
Negative_regulation (inhibition) of Localization (secretion) of AVP in proximal associated with diuresis
7) Confidence 0.59 Published 1995 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 8542675 Disease Relevance 0.17 Pain Relevance 0
We conclude that the inhibition of the release of AVP is the major if not the entire mechanism of the diuretic action of U-62,066E in rats.
Negative_regulation (inhibition) of Localization (release) of AVP
8) Confidence 0.58 Published 1989 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2547626 Disease Relevance 0.18 Pain Relevance 0.23
When applied to the hypothalamus, nanomolar concentrations of BRL inhibited osmotically stimulated AVP secretion.
Negative_regulation (inhibited) of Localization (secretion) of AVP in hypothalamus
9) Confidence 0.58 Published 1996 Journal Am. J. Physiol. Section Abstract Doc Link 8779961 Disease Relevance 0.08 Pain Relevance 0.49
This dose of BRL, administered to the posterior pituitary compartment, did not appear to act by the agonist gaining access to hypothalamic kappa-opiate receptors, because BNI added to the hypothalamus failed to prevent the inhibition of AVP secretion.
Negative_regulation (inhibition) of Localization (secretion) of AVP in hypothalamus associated with agonist and opiate
10) Confidence 0.58 Published 1996 Journal Am. J. Physiol. Section Abstract Doc Link 8779961 Disease Relevance 0.06 Pain Relevance 0.66
Although several studies indicate that kappa-opioid agonists induce a water diuresis by inhibiting vasopressin (AVP) secretion, the locus of the kappa-receptors (neurohypophysial vs. hypothalamic) responsible for this effect remains unclear.
Negative_regulation (inhibiting) of Localization (secretion) of vasopressin associated with diuresis and mu agonist
11) Confidence 0.58 Published 1996 Journal Am. J. Physiol. Section Abstract Doc Link 8779961 Disease Relevance 0.10 Pain Relevance 0.31
However, osmotically stimulated AVP release was suppressed at the neurohypophysial site only by 100 nM BRL and was not reversed by BNI but only by naloxone.
Negative_regulation (suppressed) of Localization (release) of AVP associated with narcan
12) Confidence 0.58 Published 1996 Journal Am. J. Physiol. Section Abstract Doc Link 8779961 Disease Relevance 0.08 Pain Relevance 0.63
Data suggest that kappa opioid agonist-induced water diuresis involves inhibition of vasopressin (AVP) secretion; however, it is not clear whether this action involves kappa receptors in the neurohypophysis or receptors behind the blood-brain barrier (BBB).
Negative_regulation (inhibition) of in neurohypophysis Localization (secretion) of AVP in blood associated with diuresis and mu agonist
13) Confidence 0.58 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8392549 Disease Relevance 0.17 Pain Relevance 0.25
The data demonstrate that opiate receptors behind the BBB are primarily involved in kappa agonist-induced water diuresis and possibly inhibition of AVP secretion.
Spec (possibly) Negative_regulation (inhibition) of Localization (secretion) of AVP associated with diuresis, agonist and opiate
14) Confidence 0.58 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8392549 Disease Relevance 0.35 Pain Relevance 0.29
The data are consistent with the hypothesis that kappa agonists inhibit release of vasopressin from the neurohypophysis and this decrease in vasopressin release leads to increased urination.
Negative_regulation (inhibit) of Localization (release) of vasopressin in neurohypophysis associated with agonist and overactive bladder
15) Confidence 0.58 Published 1983 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 6137557 Disease Relevance 0.96 Pain Relevance 1.11
The results indicate that clonidine-induced diuresis is centrogenic and is attributed to the inhibition of the release of vasopressin from central hypothalamoneurohypophyseal axis.
Negative_regulation (inhibition) of Localization (release) of vasopressin associated with diuresis and clonidine
16) Confidence 0.58 Published 1985 Journal Acta Pharmacol Toxicol (Copenh) Section Abstract Doc Link 3993390 Disease Relevance 0.10 Pain Relevance 0.51
When AVP secretion is reduced, an exponential decay of plasma AVP concentration was introduced in our model.
Negative_regulation (reduced) of Localization (secretion) of AVP in plasma
17) Confidence 0.58 Published 2010 Journal BMC Physiol Section Body Doc Link PMC2939538 Disease Relevance 0.13 Pain Relevance 0
These findings demonstrate that ionotropic excitatory amino acids agonists inhibit vasopressin secretion from hypothalamic slices.
Negative_regulation (inhibit) of Localization (secretion) of vasopressin associated with agonist and excitatory amino acid
18) Confidence 0.58 Published 2000 Journal J. Neuroendocrinol. Section Abstract Doc Link 11012837 Disease Relevance 0 Pain Relevance 0.53
Incubation with 1 x 10-4 M tetrodotoxin did not change basal vasopressin release, but it blocked the decrease in vasopressin secretion induced by 1 x 10-7 M NMDA or 1 x 10-6 M kainate or 1 x 10-6 M AMPA.
Negative_regulation (blocked) of Localization (secretion) of vasopressin associated with tetrodotoxin
19) Confidence 0.58 Published 2000 Journal J. Neuroendocrinol. Section Abstract Doc Link 11012837 Disease Relevance 0 Pain Relevance 0.54
Incubation with 1 x 10-6 M GABA alone decreased vasopressin secretion to 64.6 +/- 6.9% of control values.
Negative_regulation (decreased) of Localization (secretion) of vasopressin associated with gaba
20) Confidence 0.58 Published 2000 Journal J. Neuroendocrinol. Section Abstract Doc Link 11012837 Disease Relevance 0 Pain Relevance 0.59

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox